• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非免疫功能低下个体中持续存在具有临床意义水平的 SARS-CoV2 包膜基因亚基因组 RNA。

Persistence of clinically relevant levels of SARS-CoV2 envelope gene subgenomic RNAs in non-immunocompromised individuals.

机构信息

Institute of Clinical and Biomedical Sciences, University of Exeter, RILD building, Royal Devon and Exeter Hospital (Wonford), Barrack Road, Exeter, UK.

NIHR Exeter Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Royal Devon and Exeter Hospital, Barrack Road, Exeter, UK.

出版信息

Int J Infect Dis. 2022 Mar;116:418-425. doi: 10.1016/j.ijid.2021.12.312. Epub 2021 Dec 7.

DOI:10.1016/j.ijid.2021.12.312
PMID:34890790
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8757659/
Abstract

OBJECTIVES

This study aimed to evaluate the associations between COVID-19 severity and active viral load, and to characterize the dynamics of active SARS-CoV-2 clearance in a series of archival samples taken from patients in the first wave of COVID-19 infection in the South West of the UK.

METHODS

Subgenomic RNA (sgRNA) and E-gene genomic sequences were measured in a retrospective collection of PCR-confirmed SARS-CoV-2-positive samples from 176 individuals, and related to disease severity. Viral clearance dynamics were then assessed in relation to symptom onset and last positive test.

RESULTS

Whilst E-gene sgRNAs declined before E-gene genomic sequences, some individuals retained sgRNA positivity for up to 68 days. 13% of sgRNA-positive cases still exhibited clinically relevant levels of virus after 10 days, with no clinical features previously associated with prolonged viral clearance times.

CONCLUSIONS

Our results suggest that potentially active virus can sometimes persist beyond a 10-day period, and could pose a potential risk of onward transmission. Where this would pose a serious public health threat, additional mitigation strategies may be necessary to reduce the risk of secondary cases in vulnerable settings.

摘要

目的

本研究旨在评估 COVID-19 严重程度与活病毒载量之间的关联,并描述在英国西南部 COVID-19 感染第一波期间从患者中采集的一系列存档样本中活 SARS-CoV-2 清除的动力学特征。

方法

对来自 176 名经 PCR 确证的 SARS-CoV-2 阳性样本的回顾性采集进行亚基因组 RNA(sgRNA)和 E 基因基因组序列测量,并与疾病严重程度相关联。然后,根据症状发作和最后一次阳性检测来评估病毒清除动力学。

结果

尽管 E 基因 sgRNA 在 E 基因基因组序列之前下降,但一些个体的 sgRNA 阳性持续时间长达 68 天。在 10 天后,仍有 13%的 sgRNA 阳性病例表现出有临床意义的病毒载量,且没有以前与延长病毒清除时间相关的临床特征。

结论

我们的结果表明,潜在的活病毒有时可能会持续存在超过 10 天,这可能构成潜在的传播风险。如果这对公共卫生构成严重威胁,可能需要采取额外的缓解策略,以减少在脆弱环境中发生二次感染的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d9/8757659/8988ad86630a/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d9/8757659/81ba59376628/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d9/8757659/99a1fb0fba91/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d9/8757659/71714f83d861/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d9/8757659/8988ad86630a/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d9/8757659/81ba59376628/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d9/8757659/99a1fb0fba91/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d9/8757659/71714f83d861/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d9/8757659/8988ad86630a/gr4_lrg.jpg

相似文献

1
Persistence of clinically relevant levels of SARS-CoV2 envelope gene subgenomic RNAs in non-immunocompromised individuals.非免疫功能低下个体中持续存在具有临床意义水平的 SARS-CoV2 包膜基因亚基因组 RNA。
Int J Infect Dis. 2022 Mar;116:418-425. doi: 10.1016/j.ijid.2021.12.312. Epub 2021 Dec 7.
2
Profiling of SARS-CoV-2 Subgenomic RNAs in Clinical Specimens.SARS-CoV-2 亚基因组 RNA 在临床标本中的分析。
Microbiol Spectr. 2022 Apr 27;10(2):e0018222. doi: 10.1128/spectrum.00182-22. Epub 2022 Mar 21.
3
Clinical utility of SARS-CoV-2 subgenomic RT-PCR in a pediatric quaternary care setting.在儿科四级医疗机构中,SARS-CoV-2 亚基因组 RT-PCR 的临床实用性。
J Clin Virol. 2023 Jul;164:105494. doi: 10.1016/j.jcv.2023.105494. Epub 2023 May 18.
4
Characterizing SARS-CoV-2 Transcription of Subgenomic and Genomic RNAs During Early Human Infection Using Multiplexed Droplet Digital Polymerase Chain Reaction.采用多重数字微滴 PCR 技术对早期人类感染中 SARS-CoV-2 亚基因组和基因组 RNA 的转录进行特征分析。
J Infect Dis. 2023 Apr 18;227(8):981-992. doi: 10.1093/infdis/jiac472.
5
Detectable Duration of Viable SARS-CoV-2, Total and Subgenomic SARS-CoV-2 RNA in Noncritically Ill COVID-19 Patients: a Prospective Cohort Study.非危重新冠肺炎患者中可检测到的存活 SARS-CoV-2、总 SARS-CoV-2 RNA 和亚基因组 SARS-CoV-2 RNA 的持续时间:一项前瞻性队列研究。
Microbiol Spectr. 2022 Jun 29;10(3):e0050322. doi: 10.1128/spectrum.00503-22. Epub 2022 May 23.
6
Severe Acute Respiratory Syndrome Coronavirus 2 Normalized Viral Loads and Subgenomic RNA Detection as Tools for Improving Clinical Decision Making and Work Reincorporation.严重急性呼吸综合征冠状病毒 2 归一化病毒载量和亚基因组 RNA 检测作为改善临床决策和重返工作岗位的工具。
J Infect Dis. 2021 Oct 28;224(8):1325-1332. doi: 10.1093/infdis/jiab394.
7
Secondary Structure of Subgenomic RNA M of SARS-CoV-2.SARS-CoV-2 的亚基因组 RNA M 的二级结构。
Viruses. 2022 Feb 4;14(2):322. doi: 10.3390/v14020322.
8
Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients.严重 COVID-19 患者中两种 SARS-CoV-2 亚基因组 RNA 动力学特征。
Virol Sin. 2022 Feb;37(1):30-37. doi: 10.1016/j.virs.2022.01.008. Epub 2022 Jan 17.
9
SARS-CoV-2 Virus Culture, Genomic and Subgenomic RNA Load, and Rapid Antigen Test in Experimentally Infected Syrian Hamsters.实验感染叙利亚仓鼠中 SARS-CoV-2 病毒培养、基因组和亚基因组 RNA 载量及快速抗原检测。
J Virol. 2022 Sep 28;96(18):e0103422. doi: 10.1128/jvi.01034-22. Epub 2022 Aug 30.
10
Diagnostic usefulness of subgenomic RNA detection of viable SARS-CoV-2 in patients with COVID-19.亚基因组 RNA 检测在 COVID-19 患者中对活 SARS-CoV-2 的诊断价值。
Clin Microbiol Infect. 2022 Jan;28(1):101-106. doi: 10.1016/j.cmi.2021.08.009. Epub 2021 Aug 13.

引用本文的文献

1
Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID-19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial.依特司韦单抗治疗无症状或轻度 COVID-19 的疗效和安全性:一项多中心、随机、2b/3 期临床研究的探索性分析。
Influenza Other Respir Viruses. 2024 Jun;18(6):e13338. doi: 10.1111/irv.13338.
2
A retrospective study suggests 55 days of persistence of SARS-CoV-2 during the first wave of the pandemic in Santiago de Chile.一项回顾性研究表明,在智利圣地亚哥第一波疫情期间,新冠病毒(SARS-CoV-2)持续存在了55天。
Heliyon. 2024 Jan 18;10(7):e24419. doi: 10.1016/j.heliyon.2024.e24419. eCollection 2024 Apr 15.
3

本文引用的文献

1
India's massive COVID surge puzzles scientists.印度新冠疫情的大规模激增令科学家们感到困惑。
Nature. 2021 Apr;592(7856):667-668. doi: 10.1038/d41586-021-01059-y.
2
Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England.评估 SARS-CoV-2 谱系 B.1.1.7 在英国的传播能力。
Nature. 2021 May;593(7858):266-269. doi: 10.1038/s41586-021-03470-x. Epub 2021 Mar 25.
3
SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis.SARS-CoV-2、SARS-CoV 和 MERS-CoV 的病毒载量动态、病毒脱落持续时间和传染性:系统评价和荟萃分析。
Quantitative SARS-CoV-2 subgenomic RNA as a surrogate marker for viral infectivity: Comparison between culture isolation and direct sgRNA quantification.
定量 SARS-CoV-2 亚基因组 RNA 作为病毒感染性的替代标志物:培养分离与直接 sgRNA 定量的比较。
PLoS One. 2023 Sep 1;18(9):e0291120. doi: 10.1371/journal.pone.0291120. eCollection 2023.
4
Analytical validation of quantitative SARS-CoV-2 subgenomic and viral load laboratory developed tests conducted on the Panther Fusion® (Hologic) with preliminary application to clinical samples.对 Panther Fusion®(Hologic)上进行的定量 SARS-CoV-2 亚基因组和病毒载量实验室开发检测的分析验证,初步应用于临床样本。
PLoS One. 2023 Jun 29;18(6):e0287576. doi: 10.1371/journal.pone.0287576. eCollection 2023.
5
Comparative subgenomic mRNA profiles of SARS-CoV-2 Alpha, Delta and Omicron BA.1, BA.2 and BA.5 sub-lineages using Danish COVID-19 genomic surveillance data.利用丹麦 COVID-19 基因组监测数据比较 SARS-CoV-2 Alpha、Delta 和 Omicron BA.1、BA.2 和 BA.5 亚谱系的亚基因组 mRNA 图谱。
EBioMedicine. 2023 Jul;93:104669. doi: 10.1016/j.ebiom.2023.104669. Epub 2023 Jun 20.
6
Characterizing SARS-CoV-2 Transcription of Subgenomic and Genomic RNAs During Early Human Infection Using Multiplexed Droplet Digital Polymerase Chain Reaction.采用多重数字微滴 PCR 技术对早期人类感染中 SARS-CoV-2 亚基因组和基因组 RNA 的转录进行特征分析。
J Infect Dis. 2023 Apr 18;227(8):981-992. doi: 10.1093/infdis/jiac472.
7
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.一项评估新型口服 SARS-CoV-2 3CL 蛋白酶抑制剂恩赛特韦(ensitrelvir)在日本轻至中度 COVID-19 或无症状 SARS-CoV-2 感染患者中的疗效和安全性的随机 2/3 期研究:2a 期部分结果。
Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0069722. doi: 10.1128/aac.00697-22. Epub 2022 Sep 13.
8
Secondary Attack Rate, Transmission and Incubation Periods, and Serial Interval of SARS-CoV-2 Omicron Variant, Spain.奥密克戎变异株的二次感染率、传播和潜伏期以及间隔时间,西班牙。
Emerg Infect Dis. 2022 Jun;28(6):1224-1228. doi: 10.3201/eid2806.220158. Epub 2022 Apr 7.
Lancet Microbe. 2021 Jan;2(1):e13-e22. doi: 10.1016/S2666-5247(20)30172-5. Epub 2020 Nov 19.
4
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence.尽管血清阳性率很高,巴西玛瑙斯仍出现新冠病毒的卷土重来。
Lancet. 2021 Feb 6;397(10273):452-455. doi: 10.1016/S0140-6736(21)00183-5. Epub 2021 Jan 27.
5
Local Transmission of SARS-CoV-2 Lineage B.1.1.7, Brazil, December 2020.2020 年 12 月,巴西出现的 SARS-CoV-2 谱系 B.1.1.7 的本地传播。
Emerg Infect Dis. 2021 Mar;27(3):970-972. doi: 10.3201/eid2703.210038. Epub 2021 Jan 26.
6
Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques.严重急性呼吸综合征冠状病毒2感染的恒河猴亚基因组RNA与总RNA的比较
J Virol. 2021 Mar 25;95(8). doi: 10.1128/JVI.02370-20. Epub 2021 Jan 20.
7
Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19).COVID-19 住院患者中感染性病毒排出的持续时间和关键决定因素。
Nat Commun. 2021 Jan 11;12(1):267. doi: 10.1038/s41467-020-20568-4.
8
Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020.2020 年 10 月至 11 月英国 SARS-CoV-2 N501Y 突变株的早期传播能力评估。
Euro Surveill. 2021 Jan;26(1). doi: 10.2807/1560-7917.ES.2020.26.1.2002106.
9
Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer.癌症免疫抑制治疗后活的严重急性呼吸综合征冠状病毒2的脱落
N Engl J Med. 2020 Dec 24;383(26):2586-2588. doi: 10.1056/NEJMc2031670. Epub 2020 Dec 1.
10
Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer.病例研究:一名患有癌症的无症状免疫功能低下个体长期感染性严重急性呼吸综合征冠状病毒2(SARS-CoV-2)脱落。
Cell. 2020 Dec 23;183(7):1901-1912.e9. doi: 10.1016/j.cell.2020.10.049. Epub 2020 Nov 4.